

## PATIENT INFORMATION

PATIENT NAME: \_\_\_\_\_ PHONE: \_\_\_\_\_

DATE OF BIRTH: \_\_\_\_\_ SEX: ☐ M ☐ F HEIGHT: \_\_\_\_\_ WEIGHT: \_\_\_\_\_ ☐ LBS ☐ KG

ALLERGIES: \_\_\_\_\_ PREFERRED CLINIC: \_\_\_\_\_

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

## DIAGNOSIS & CLINICAL DOCUMENTATION

- |  |  |
|--|--|
| <input type="checkbox"/> D59.30 Hemolytic Uremic Syndrome (aHUS)         | <input type="checkbox"/> G70.00 Myasthenia Gravis without acute exacerbation |
| <input type="checkbox"/> D59.5 Paroxysmal nocturnal hemoglobinuria (PNH) | <input type="checkbox"/> G70.01 Myasthenia Gravis with acute exacerbation    |
| <input type="checkbox"/> G36.0 Neuromyelitis optica (NMOSD)              |  |
| <input type="checkbox"/> ICD-10 CODE: _____ DESCRIPTION: _____           |  |

## REQUIRED DOCUMENTATION

- ☐ Insurance Information
 ☐ List of Medications
 ☐ Tried & failed Therapies
 ☐ Most recent History & Physical
 ☐ Anti-AChR or Anti-AQP4 Status
 ☐ Meningococcal vaccine records

## MEDICATION ORDER

## PRE-MEDICATIONS

### PO

- ☐ Acetaminophen: 650 mg  
☐ Cetirizine: 10 mg  
☐ Diphenhydramine: 25 mg

### IV

- ☐ Methylprednisolone: 125 mg  
☐ Diphenhydramine: 25 mg

☐ OTHER: \_\_\_\_\_ ☐ PO ☐ IV

### \*For Patients Weighing 40 kg to 59 kg

- ☐ **LOADING:** Ultomiris® (ravulizumab) 2400 mg IV per protocol at week 0, and 3000 mg IV at week 2  
☐ **MAINTENANCE:** Ultomiris® (ravulizumab) 3000 mg IV per protocol every 8 weeks

### \*For Patients Weighing 60 kg to 100 kg

- ☐ **LOADING:** Ultomiris® (ravulizumab) 2700 mg IV per protocol at week 0, and 3300 mg IV at week 2  
☐ **MAINTENANCE:** Ultomiris® (ravulizumab) 3300 mg IV per protocol every 8 weeks

### \*For Patients Weighing GREATER Than 100 kg

- ☐ **LOADING:** Ultomiris® (ravulizumab) 3000 mg IV per protocol at week 0, and 3600 mg IV at week 2  
☐ **MAINTENANCE:** Ultomiris® (ravulizumab) 3600 mg IV per protocol every 8 weeks

☐ **OTHER:** \_\_\_\_\_  
 \*Flush with 30 ml NS after each infusion

☒ REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE: \_\_\_\_\_

Patient to be observed for 60 minutes following each infusion.  
 In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

## PRESCRIBER INFORMATION

PROVIDER NAME: \_\_\_\_\_ NPI #: \_\_\_\_\_

EMAIL: \_\_\_\_\_ PHONE: \_\_\_\_\_ FAX: \_\_\_\_\_

ADDRESS (INCLUDE CITY, STATE, ZIP): \_\_\_\_\_

SUPERVISING PHYSICIAN: \_\_\_\_\_ CONTACT NAME: \_\_\_\_\_  
(IF APPLICABLE)

SIGNATURE: \_\_\_\_\_ DATE: \_\_\_\_\_  
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN